In order to assess the role of NOD2/CARD15 variants on the long term outcome of allogeneic stem cell transplantation in a genetically homogenous group, we extended our previous study (cohort I, n=78) and typed DNA from additional 225 recipients and their HLA-identical sibling donors (cohort II) from 4 European centres for NOD2/CARD15 SNPs. Results of genotyping were compared with clinical outcome: The strong association of NOD2/CARD15 variants with transplant related mortality (TRM) was confirmed in univariate and multivariate analysis: TRM increased from 20% in cohort I/ 22% in cohort II in recipient/donor pairs without any NOD2/CARD15 variants to 47% (cohort I)/ 32% (cohort II) in the presence of 1 variant in either donor or recipient and further to 57% (cohort I) / 74% (cohort II) in the presence of 2 or more variants (p 0.002 in both cohorts). NOD2/CARD15 SNPs were not associated with relapse rate but had a strong impact on overall survival. In an analysis of centre effects, the type of gastrointestinal decontamination was the only factor interfering with the prognostic significance of NOD2/CARD15 SNPs. Our data further support an interaction between gastrointestinal defense mechanisms, activation of the innate immune system and specific transplant related complications.
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Introduction:
Pathophysiological concepts of graft-versus-host disease (GvHD) have been based on several hypotheses: Although there is no doubt that activation of donor T lymphocytes is the central event in the alloreactivity, the concomitant interaction of the innate immune system also plays an important role and has been conceptually addressed by several investigators: Van Bekkum´s findings on prevention of GvHD by breeding mice under germfree conditions initiated a longstanding discussion on the role of gnotobiotic prophylaxis and the mechanisms of interaction between microbial and specific Tcell activation. With description of cytokines as major effectors of at least acute GvHD the endotoxin hypothesis postulated that the translocation of bacterial toxins across the gastrointestinal mucosa gave rise to co-stimulation of cytokine release and an alloimmune response. However, the findings of Beelen et al 4 demonstrating a strong effect of elimination of anaerobic bacteria on GvHD in patients, and the recent observations that mice lacking Peyer´s patches or receiving prophylaxis with lactobacilli have a strongly reduced incidence of GvHD, suggested again a more direct interaction of bacterial ligands and activation of specific immune responses.
Recently, our group reported a significant association between the occurrence of single nucleotide polymorphisms (SNPs) within the NOD2/CARD15 gene and GvHD as well as transplant related mortality (TRM) 7 .The NOD2/CARD15 gene had been identified as the first "susceptibility" or "disease" gene in Crohn´s disease, a form of inflammatory bowel disease 8, 9 . It codes for an intracytoplasmatic sensor of the bacterial cell wall compound muramyldipeptide (MDP). Ligation of MDP to NOD2/CARD15 induces a signal transduction cascade finally leading to activation of the transcription factor NF-B and subsequent inflammatory response in epithelial cells of the ileum 10 as well as in monocyte/macrophage derived cells.
As the first series analysed consisted of a heterogeneous group of allogeneic HLA-identical sibling and unrelated donor HSCT it did not allow a more detailed analysis within these genetically different transplant groups. Therefore we now have performed an analysis focussing only on HLA-identical sibling transplants including patients from the first cohort and a larger, 2 nd and independent cohort of patients, and addressed the impact of NOD2/CARD15 SNPs on long term transplant outcome. The strong impact of NOD2/CARD15 variants on acute GvHD and early TRM was confirmed and translated as strong impact on long term overall survival. Furthermore, our data suggest an interference of NOD2/CARD15 genotype with prophylactic use of gastrointestinal decontamination.
Material and Methods:
Patients and Donors: 303 consecutive patients from 5 different centres were included in this analysis, the cohort of 78 patients from Regensburg (centre 1; Cohort I) had been partially included in our first single centre report on the role of NOD2/CARD15 in allogeneic HSCT but so far not been analysed for long term outcome. To these 78 patients, 225 patients (Cohort II) were added from the centres of Vienna (centre 2; n=38), Newcastle (centre 3; n=90), Rostock (centre 4; n=37) and Paris (centre 5; n=60). All patients received grafts from HLA-identical sibling donors. Significance testing was performed by using the likelihood ratio test (p < 0.05). For calculation of TRM, incidence of GvHD and relapse, the cumulative incidence method with either relapse or non-relapse related mortality treated as competing risks was used with the help of the NCSS 2004 software (NCSS, Kaysville , USA). All group comparisons were done using Fisher´s exact test (p-values < 0.05 were considered as statistically significant).
Results:

Distribution of NOD2/CARD15 variants and number of NOD variants in the transplant cohorts
As shown in table 2, the distribution of NOD2/CARD15 variants within recipients and donors as well as the distribution of the number of NOD2/CARD15 variants were similar in both cohorts of patients.
Effect of NOD2/CARD15 variants on GvHD III/IV, 1 yr TRM and overall TRM in both cohorts:
When we checked the impact of NOD2/CARD15 variants on major outcome variables, similar associations were observed in both cohorts. Although the relative increases in incidences seemed to be more pronounced in cohort I as compared to Cohort II, results were uniformly significant for all major parameters (table 3) including GVHD III/IV, gastrointestinal GvHD, 1 yr TRM, overall TRM. Causes of death were comparable in both cohorts: Death could be directly attributed to GvHD in 24%, to major bacterial or viral infection in 19%, to fungal infections in 10%, to primary or secondary respiratory failure in 35% and to organ toxicities in 12%. Within patients with NOD2/CARD15 mutations, there was a trend to a higher proportion of patients dying from respiratory failure (data not shown).
Multivariate cox regression analysis including major known risk factors such as older age (>40yrs), diagnosis, status of disease at the time of HSCT, gender combination, type of gastrointestinal decontamination, intensity of conditioning and stem cell source confirmed the impact of NOD2/CARD15 status, especially for the high risk group bearing 2 or more variants, as the only significant and independent risk factors for TRM in both cohorts of patients (table 4a) .
Long term effects: Association of NOD2/CARD15 variants with TRM demonstrates a strong impact on overall survival
In contrast to TRM, NOD2/CARD15 status had no major impact on relapse incidence and relapse related mortality: For all patients, cumulative incidence of relapse related mortality Thus, association of NOD2/CARD15 status with TRM demonstrated a strong and highly significant impact on overall survival for the whole group of patients (figure 1) but also for individual cohorts (wt cohort I 60%, cohort II 53%; 1 variant: cohort I 15%, cohort II 47%; 2 or more variants: cohort I 0%, cohort II 21%; log rank for cohort I p 0.001, for cohort II 0.02).
In multivariate analysis, NOD2/CARD15 status remained the only significant factor associated with survival in both cohorts whereas advanced stage was of significance (HR 2.67; 95% CI Centre effects may be explained by the type of gastrointestinal decontamination
As associations of NOD2/CARD15 seemed to be less stringent in cohort II when compared to our first series we checked for the prognostic role of NOD2/CARD15 in individual centres.
Although influenced by different numbers of patients, the overall role of NOD2/CARD15
seemed to be consistently strong in 3 centres but less clear in 2 others. Significant associations for both, TRM and overall survival were observed in centres 1, 3 and 4, whereas minor trends occurred in centres 2 and 5 (table 5).
As patient and transplant characteristics showed major differences between centres we next checked whether these factors interfered with the prognostic significance of NOD2/CARD15.
After stratification for risk factors differing between participating centres such as age of the patient, status of disease at the time of HSCT, underlying disease, standard versus reduced intensity conditioning and marrow versus PBSC as stem cell source, NOD2/CARD15 remained a significant risk factor for GvHD and overall TRM in the subgroups. However, after stratification for the type of intestinal decontamination, the clear effect of NOD2/CARD15 variants on GvHD and overall TRM was only seen in patients receiving decontamination with ciprofloxacine or no decontamination at all (as used in centres 1,3 and 4, group 1) but was strongly reduced in patients receiving decontamination including gram- 
Discussion:
After our first report on an association of NOD2/CARD15 variants with GvHD and transplant related mortality following allogeneic SCT, we now were able to extend our observations to a 2 nd independent cohort and to analyse for the first time a genetically homogenous group of HLA-identical sibling transplants and their respective donors from 5 different European centres. Our data not only confirm the previously reported associations in a large second cohort but also add substantial new information on the role of NOD2/CARD15 SNPs with regard to long term outcome, graft-versus leukaemia effects, the potential role of gene dosage and of interfering factors.
Within the large and genetically homogenous group of HLA-identical sibling transplants we analysed the long term effect of NOD2/CARD15 mutations on transplant outcome. Many strategies or factors associated with GvHD are inversely and directly linked to the major therapeutic principle of allogeneic SCT, the graft-versus-leukemia (GvL) effect, and patients with severe GvHD have a low risk of relapse and vice versa 12, 13 . In contrast, analysis of survivors with NOD2/CARD15 variants indicated an almost identical cumulative incidence of relapse in all cohorts. As a result, the NOD2/CARD15 status had a strong and independent influence on overall survival. This influence was also stronger than the role of the otherwise most established clinical risk factor, the status of disease at time of HSCT. Thus, our data gives rise to the hypothesis that the part of the pathophysiology of GvHD, which links the interactions of microbial load with innate immunity and the activation of the specific immune response, is not directly involved in GvL effects. This hypothesis would be in line with experimental results suggesting that modulating the inflammatory pathway induced by LPS prevents GvHD but spares GvL effects 14 . Furthermore, absence of cross-reaction between bacterial antigens in the gut and tumor antigens may also be derived from careful analysis of risks for various non-gastrointestinal cancers in patients suffering from Crohn´s disease as these studies did not reveal any protective effect of intestinal inflammation 15 .
So far, we do not know exactly, how an impaired function of NOD2/CARD15 may mediate GvHD and transplant related mortality. The paradigm of a (at least partial) NOD2/CARD15
defect and an increased susceptibility to inflammation has been extensively discussed in the setting of Crohn´s disease 16 , as both, gain of function with increased IL1ß driven inflammation 17 and loss of function with deficient NF B response, and NFkB dependent inflammation 18 and bacterial killing 19 variants in a larger prospective series of patients is urgently needed.
In our previous paper, we reported the strongest association of NOD2/CARD15 variants with outcome in patients with combined donor/recipient variants. Combined donor/recipient variants may have the strongest impact on GvHD and TRM because of the additive effects of damage in affected cells, e.g. recipient epithelium and donor monocytes but also represent an additive effect of mutation dose in macrophage-derived cells of the donor and the recipient.
As mutation dose of NOD2/CARD15 has been shown to have a strong impact not only on the relative risk of Crohn´s diseases but also on functional defects like MDP induced IL-8 secretion [21] [22] [23] we preferred to perform the present analysis based on the number of variants present in an individual donor/recipient pair and were able to show strong cumulative effects.
However, the evaluation of the exact contribution of donor and recipient cells and the respective cellular components will require sophisticated mouse experiments addressing isolated NOD2/CARD15 deficiencies in donors and recipients and T cell versus macrophage populations.
Clinically, it might be desirable but difficult to overcome the impact of NOD2/CARD15
variants by altered prophylactic strategies. Selecting an alternative donor might be helpful 
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